United States Patent 10,213,486: What the Claims Actually Cover and How the Landscape Looks
United States Patent 10,213,486 claims a homeopathic-style serial dilution process for a specific “amino acid fragment” defined by sequence identity to the N-terminal end of the beta subunit of human chorionic gonadotropin (hCG-β) (and in dependent claims optionally also the alpha subunit terminal end). The method requires producing an end product with ultra-low concentration of the amino acid fragment, specifically ≤ 1 × 10^-10 w/w, using serial dilution with optional successive succussion steps. The claims extend to a packaged homeopathic formulation made by the recited method, including multiple dosage forms.
What is claimed, in plain technical terms?
The independent claim language is structured around five technical pillars:
-
Starting material identity
- “Amino acid fragment” includes a peptide sequence of at least five amino acids that is the same as the N-terminal end of the beta subunit of human chorionic gonadotropin.
- The fragment is not the same as the complete peptide sequence of either the alpha or beta subunit of hCG.
-
Serial dilution to an ultra-low end concentration
- The method mixes the fragment with a “diluting agent,” then serially dilutes at least a portion to reach a diluted formulation with concentration ≤ 1 × 10^-10 w/w.
-
Mixing mechanics
- Claim 1: “serially diluting… and vigorously mixing each increasingly dilute mixture.”
- Claim 14 (succussed variant): “repeatedly diluting” and succussing each increasingly dilute mixture.
-
Process constraints (dilution ratio and number of steps)
- Average dilution ratio ≤ about 1:5 (dependent claim 11).
- Serial dilution at least three times (dependent claim 12).
- Same dilution ratio used each time (dependent claim 10, and mirrored in claim 20).
- Dilution repeated to yield at least three increasingly dilute mixtures (claim 22).
-
Potency and compositional distribution
- Dependent claim 13: “potency … at least 20V, 10X, or 5C.”
- Dependent claim 8/19: ≥ 50% w/w of amino acid fragments in the mixture contain the specified hCG-β N-terminal sequence, and those fragments are not the complete alpha or beta subunit sequences.
What do dependent claims expand or narrow?
Peptide length scaling
Claims define broader coverage as the required peptide sequence length increases:
| Claim set |
Required peptide sequence length requirement |
Must match |
Additional constraint |
| 1 |
≥ 5 aa |
hCG-β N-terminal end |
Not the complete alpha or beta subunit sequence |
| 2-4 |
≥ 10 / ≥ 15 / ≥ 20 aa |
hCG-β N-terminal end |
Same “not complete subunit” constraint |
| 5-7 |
peptide is “first peptide sequence”; fragment includes “second peptide sequence” |
hCG-α terminal end |
Same “not complete subunit” framework remains embedded via claim 1/14 context |
| 6-8 |
second sequence defined further |
hCG-α N-terminal terminal end (as recited) |
Adds length thresholds (≥10 in claim 7) |
Composition fraction control
Claims 8 and 19 require a bulk compositional rule:
- ≥ 50% w/w of amino acid fragments must each include a peptide sequence matching the hCG-β N-terminal end (≥5 aa).
- Those fragments are not the complete alpha or beta subunit peptide sequences.
This targets mixtures that might contain multiple fragment types, ensuring at least half the mass satisfies the sequence-identity requirement.
Dilution ratio and step count
The dependent process parameters are consistent and relatively tight:
- Average dilution ratio ≤ about 1:5 (claims 11 and 21).
- At least three serial dilution rounds (claims 12 and 22).
- “Same dilution ratio” across rounds (claims 10 and 20).
Potency language
Claim 13 uses homeopathy potency nomenclature (“V”, “X”, “C”). It does not define conversion logic in the provided claims text. It still sets a minimum potency category:
- “potency of the diluted formulation is at least 20V, 10X, or 5C.”
What is claim 14 adding beyond claim 1?
Claim 14 is a process variant that adds succussing:
- Serial dilution becomes “repeatedly diluting” to successive increasingly dilute mixtures.
- Succussing each increasingly dilute mixture is a required step.
- The same end concentration cap (≤ 1 × 10^-10 w/w) and the same peptide identity constraints apply.
This creates a separation in infringement analysis:
- A manufacturer that dilutes without succussing is closer to claim 1 coverage than claim 14 coverage (and vice versa).
How broad are these claims, and where are the critical choke points?
Claim scope summary
The claims cover:
- Method of preparing a homeopathic formulation from a defined hCG-derived peptide fragment (N-terminal hCG-β; and optionally hCG-α terminal end in dependent claims).
- Process includes serial dilution to an extremely low concentration with tight constraints on dilution behavior (mixing/vigorous mixing; or succussion).
- End concentration ceiling is explicitly set: ≤ 10^-10 w/w.
- Packaged product created by the method (container + label) and spanning at least liquid, and potentially pellet/tablet/capsule dosage forms.
Choke points that materially narrow infringement risk
The most determinative limitations are:
-
Sequence identity requirement
- At least one peptide fragment element must have a sequence identical to a specific region of hCG-β (N-terminal end).
- The fragment must be a fragment not equal to the complete alpha or beta subunit sequence.
-
Ultra-low concentration
- End concentration must be ≤ 1 × 10^-10 w/w of the amino acid fragment (not a general “high dilution” statement).
-
Dilution ratio and step count
- Average dilution ratio ≤ ~1:5 and at least three rounds.
-
Mixing vs succussing
- Claim 1 requires “vigorously mixing” each increasingly dilute mixture.
- Claim 14 requires “succussing each increasingly dilute mixture.”
- These are operationally distinct for manufacturing proof.
-
Composition fraction requirement (dependent)
- For claims 8/19, ≥50% w/w of fragments must satisfy the hCG-β N-terminal matching criterion.
Where the claim language creates ambiguity in practice
Even with the above, several features can drive real-world disputes:
- “Amino acid fragment” is not defined in the provided excerpt (e.g., whether it is a single defined oligopeptide, a mixture of fragments, or a “fragment population”).
- “Same as the N-terminal end” and “terminal end of the alpha subunit” depend on how the relevant peptide sequence boundaries are construed.
- “Potency” categories (“20V, 10X, or 5C”) are not anchored to a specific dilution math in the claim text you provided, which can matter when comparing real manufacturing records to claimed parameters.
Patent landscape: what to expect around this type of claim
Core landscape theme
This patent sits in the intersection of:
- homeopathic serial dilution/succussion methods, and
- highly specific starting-material identity tied to human chorionic gonadotropin subunits.
In the broader US practice, homeopathic method claims tend to cluster around:
- serial dilution steps,
- shaking/succussing steps,
- defined starting substances,
- end potency thresholds or dilution schemes.
The differentiator here is not homeopathy mechanics alone; it is the molecular targeting of a specific hCG-derived peptide fragment sequence region and exclusion of complete subunit sequences.
How the hCG fragment constraint affects freedom-to-operate
A competitor using any hCG-derived preparation at high dilution could still avoid this patent if it does not meet one of the key structural constraints:
- fragment sequence must match the hCG-β N-terminal end (and optionally include the hCG-α terminal end in dependent claims),
- fragment must not be the complete alpha or beta subunit sequence,
- end concentration must land at or below ≤ 10^-10 w/w,
- process must satisfy either the “vigorous mixing” route or the “succussing” route depending on which claims are asserted.
Likelihood of overlap with prior or co-existing filings
Even without enumerating specific family members here, the architecture strongly suggests overlap vectors:
- Prior homeopathic manufacturing patents likely claim serial dilution and succussion mechanics generally. Those would not necessarily contain the peptide fragment sequence identity constraint and thus would be distinguishable if the novelty hinges on the specific hCG region targeting.
- Formulations using hCG (or hCG peptides) historically exist in fertility and diagnostic contexts; however, the claimed homeopathic ultra-dilution and succussion steps are a different modality. The sequence fragment selection is the key bridge.
- If earlier filings used “dilution and succussion” with a broader “hCG” starting substance, they may still be relevant in obviousness arguments. But the claimed specificity can materially narrow that overlap.
Risk concentration
From a commercial standpoint, infringement risk clusters around:
- manufacturing documentation showing adherence to serial dilution rounds, dilution ratios, mixing/succussion, and
- evidence that the starting amino acid fragments match the specified hCG-β N-terminal sequence region and satisfy the “not complete subunit” exclusion.
Packaged formulation claim: practical enforcement angle
Claim 23
Claim 23 creates a product claim based on a method:
- “container”
- “homeopathic formulation inside the container”
- “label attached to the container”
- formulation “produced by the method recited in claim 1”
This is not limited to a single dosage form in claim 23. Dependent claims narrow it:
- Claim 30: formulation is liquid
- Claim 31: formulation is pellet, tablet, or capsule
Enforcement implication
For infringement strategy, claim 23 and its dependents are the most direct hooks for commercial products:
- the label and container are easy to identify,
- while the method compliance depends on manufacturing records or proof of process equivalence.
Critical assessment: what is strong vs what is vulnerable
Strengths
- Clear end concentration limitation: “no more than 1 × 10^-10 w/w” is a concrete numeric cap.
- Specific molecular definition: peptide sequence identity to a defined hCG-β region and explicit exclusion of complete subunit sequences narrows the universe of possible starting materials.
- Process specificity: includes at least three dilutions and limits dilution ratio to ≤ about 1:5 on average.
- Operational steps stated: “vigorously mixing” or “succussing” are concrete manufacturing actions.
Vulnerabilities (as a claim analysis)
- Homeopathic obviousness pressure: serial dilution and succussion are common in homeopathy patent literature, so novelty must rest on the peptide sequence-defined starting material and the ultra-specific constraints.
- Sequence boundary and “same as the terminal end” construction: litigation over what counts as “the N-terminal end” mapping and how peptide fragments are defined can become central.
- “Potency” category mapping: “20V, 10X, or 5C” may be attacked if the record-based equivalence to the numeric concentration cap is disputed.
- Material form uncertainty: the “amino acid fragment” definition can be attacked if prior art uses different fragment compositions that still satisfy functional identity or if the claim is interpreted broadly enough to capture heterogeneous fragment mixtures.
Key Takeaways
- US 10,213,486 is a homeopathic serial dilution patent with a sequence-defined starting material derived from hCG subunits, requiring:
- peptide identity to hCG-β N-terminal end (≥5 aa, with dependent claims extending to ≥10/≥15/≥20),
- exclusion of complete alpha/beta subunit sequences,
- serial dilution to ≤ 1 × 10^-10 w/w,
- at least three dilution rounds and average dilution ratio ≤ ~1:5,
- “vigorous mixing” (claim 1) or succussing (claim 14).
- Dependent claims tighten scope through:
- a ≥50% w/w fragment population requirement,
- optional inclusion of hCG-α terminal end peptides,
- dosage-form product coverage via packaging and labeling.
- The enforcement anchor for product makers is claim 23 (container + label + formulation produced by the method), while the practical infringement proof hinges on sequence identity and manufacturing process documentation (dilution rounds, ratios, and succussion or mixing).
FAQs
1. What is the critical numeric limitation in the patent claims?
The diluted formulation must have concentration of the amino acid fragment of no more than 1 × 10^-10 w/w.
2. Does the patent require succussion?
Only claim 14 requires succussing each increasingly dilute mixture. Claim 1 requires “vigorously mixing” instead.
3. How specific is the peptide requirement?
The amino acid fragment must include a peptide sequence that is identical to the N-terminal end of the hCG-β subunit, with dependent claims requiring peptide lengths of at least 10, 15, or 20 amino acids.
4. Does the starting material have to be exactly full-length hCG subunits?
No. The amino acid fragment must not be the same as the complete peptide sequence of either the alpha or beta subunit.
5. What does the packaging claim cover?
It covers a container with a homeopathic formulation and a label, where the formulation is produced by the method of claim 1, and dependent claims specify liquid and pellet/tablet/capsule embodiments.
References
No external sources were provided or retrieved in the prompt for citation.
